Liquidity & Technical
Liquidity & Technical
MetLife trades with deep institutional liquidity — roughly $234M of value crosses the tape on an average day, and a 5% position is implementable for funds up to about $4.9B AUM within five trading days at standard 20% participation. The technical setup is cautiously bullish: price has reclaimed the 200-day moving average and momentum has flipped positive, but the rally has carried into the upper third of the 52-week range with thin volume confirmation, and the 50-day still sits below the 200-day after a February death cross.
1. Portfolio implementation verdict
5-Day Capacity at 20% ADV ($M)
5-Day Capacity (% of Mkt Cap)
Supported AUM, 5% Position ($M)
ADV 20d / Mkt Cap (%)
Technical Stance Score
Institutionally implementable. $234M of daily traded value and 127% annual turnover place MET firmly in the deep-liquidity tier for a US insurer. A $4.9B fund can build a full 5% weight inside one trading week at a routine 20% participation rate; smaller funds face no capacity constraint at all. Liquidity is not the bottleneck — the technical setup is.
2. Price snapshot
Current Price ($)
YTD Return (%)
1-Year Return (%)
52-Week Range Position (%)
Beta (5y, vs SPY proxy)
The stock is up roughly 6% over the trailing year and sits at the 83rd percentile of its 52-week range — close to the $83.53 high but well off the all-time peak of $88.56 reached in late 2024.
3. Long-term price with 50/200 SMAs
Most recent 50/200 cross: death cross on 2026-02-25, the second of two false-start crosses in three months. The 50-day has remained below the 200-day since, indicating an unresolved trend.
Price is above the 200-day by 4.5% ($80.91 vs $77.43). The longer arc shows the trend reset clearly: a doubling from $35–40 in 2016–2018, two violent draw-downs (COVID 2020 to $24, regional-bank stress 2023 to $50), and a steady post-2023 grind into the $75–88 corridor where the stock has spent the last eighteen months chopping. This is a sideways regime, not a directional trend — five golden and five death crosses since 2023 confirm the 50/200 system is currently producing whipsaw signals around the long-run mean.
4. Relative strength
Benchmark series for SPY (broad market) and XLF (financials sector) were not staged in this run, so a direct relative-strength overlay is unavailable. As reference points, MET's 1-year, 3-year, and 5-year price returns are +5.9%, +36.1%, and +27.2% respectively — the 3-year stretch outpacing typical broad-financials returns, the 5-year lagging the broad equity market.
The 3-year rebased path shows two visible drawdowns (March 2023 banking stress and April 2025 macro shock) inside an otherwise upward trajectory. The most recent leg up — from $70 in March 2026 to $80.91 today — has been the steepest move in the series.
5. Momentum — RSI(14) and MACD histogram
RSI now reads 69.3 — one point shy of overbought — having climbed in a near-vertical line from 28 in mid-March. MACD histogram is positive (0.15) but already turning lower from a +0.93 peak two weeks ago, indicating the impulsive leg of this rally is decelerating even as price continues to grind higher. The near-term setup is stretched, not exhausted: a pullback to consolidate would be normal, and a fresh RSI cross above 70 with the histogram re-expanding would mark continuation.
6. Volume, volatility, and sponsorship
Realized 30-day volatility is 23.0%, sitting almost exactly on the 5-year median (22.9%) and well below the stressed-band threshold of 30.6%. The April 2025 spike to 55% — driven by the macro tariff/rate shock — is the lone tail event in the window; it has fully reverted. The market is not demanding a wider risk premium for MetLife right now, which is consistent with a constructive tape but undermines the case that this rally reflects fresh institutional re-rating; if real money were chasing, one would typically see implied/realized vol expand on the way up. The volume picture sharpens that read: 50-day average daily volume has been declining since February (4.1M → 3.6M shares), and the most recent week traded at 2.1M — well below trend. Most of the heavy-volume days in the table sit on the sell-side; the cleanest buy-day spike of the post-COVID era is the November 6, 2024 election rally (+6.5% on 2.8x volume).
7. Institutional liquidity panel
ADV 20d (M shares)
ADV 20d ($M)
ADV 60d (M shares)
ADV / Mkt Cap (%)
Annual Turnover (%)
Median 60-day daily range is 0.81% of price — well under the 2% threshold that would flag elevated impact cost. Bid-ask is effectively a non-issue for institutional execution at MET. The largest issuer-level position that clears in 5 trading days at 20% ADV is approximately 0.45% of market cap (≈$243M); at the more conservative 10% ADV, that figure halves to about $122M (0.22% of market cap). For typical fund mandates, a 5% portfolio weight is implementable inside a week for AUMs up to roughly $4.9B at 20% participation, or $2.4B at 10% participation. Above $5B AUM, a 5% weight becomes a multi-week build — material but routine.
The data pipeline auto-tagged this name "Illiquid / specialist only" because no listed position size at or above 0.5% of market cap exits in five days at 20% ADV (the 0.5% tier requires six). That mechanical threshold is too strict for a $54B mega-cap with 127% annual turnover and 100% volume-coverage — the practical verdict is deep institutional liquidity, with capacity-aware sizing only relevant for the largest mandates.
8. Technical scorecard and stance
Setup — cautiously constructive on the 3-to-6 month horizon. Net scorecard reads zero with one positive (momentum), one negative (resistance), and four neutrals — more constructive than it looks because price is above the 200-day, the recent move has been impulsive, and the broader 10-year arc sits at the upper end of a sideways post-2022 range. The pattern is coiled near the highs: contained vol, modest volume, fresh momentum. Two levels define the watch. A daily close above $83.53 would confirm the bullish read and open a path to $88.56 (all-time high). A loss of $77.43 (the 200-day) would invalidate it and revert the regime to the post-Feb 2026 sub-200-day chop. Liquidity is not the constraint for any fund under approximately $5B AUM at a 5% target weight; the constraint is the technical level overhead, not the size of the order book.